immun
world
popul
influenza
pandem
viru
spread
global
possibl
current
vaccin
product
platform
new
influenza
vaccin
technolog
viruslikeparticl
vlp
offer
promis
altern
test
immunogen
protect
efficaci
vlp
vaccin
contain
hemagglutinin
ha
pandem
influenza
viru
ferret
compar
intramuscular
im
intranas
rout
immun
summari
experi
demonstr
strong
immunogen
protect
efficaci
vlp
compar
split
vaccin
show
vaccin
vlp
potenti
highli
efficaci
vaccin
influenza
year
caus
signific
morbid
well
hundr
thousand
death
worldwid
addit
novel
influenza
virus
unpredict
enter
human
popul
lead
global
pandem
popul
vaccin
cornerston
public
health
program
reduc
season
pandem
influenza
morbid
mortal
inactiv
influenza
vaccin
iiv
highli
effect
prevent
diseas
caus
circul
virus
carri
neutral
epitop
present
vaccin
howev
circul
virus
rapidli
escap
host
immun
undergo
antigen
chang
maintain
efficaci
antigen
composit
iiv
updat
frequent
includ
newli
emerg
antigen
variant
recent
illustr
dramat
emerg
global
spread
swineorigin
pandem
influenza
viru
sever
approach
propos
altern
expand
vaccin
protect
antigen
variant
virus
vaccin
live
attenu
influenza
virus
laiv
given
intranas
thought
elicit
protect
immunolog
memori
heterolog
virus
elicit
mucos
well
cellular
immun
gener
weakli
induc
iiv
similarli
adjuv
vaccin
thought
elicit
protect
antigen
diverg
virus
recent
viruslik
particl
vlp
vaccin
influenza
elicit
heterosubtyp
immun
mice
ferret
intranas
intramuscular
im
administr
vlp
mimic
influenza
viru
size
structur
produc
insect
cell
recombin
baculovirus
review
refer
advantag
system
other
use
vaccin
product
includ
capac
industrialscal
synthesi
multipl
larg
protein
elimin
requir
embryon
egg
therebi
reduc
manufactur
time
vlp
comparison
convent
iiv
well
even
though
vlp
close
mimic
natur
envelop
virus
vlp
noninfecti
reduc
safeti
concern
relat
pandem
potenti
pandem
influenza
virus
also
reduc
cost
time
manufactur
vlp
immunogen
purifi
solubl
viral
protein
particul
structur
mediat
effici
uptak
antigenpres
cell
thu
elicit
effector
memori
immun
respons
without
adjuv
accumul
evid
vlp
vaccin
suggest
effici
stimul
cellular
humor
immun
respons
previou
studi
influenza
vlp
vaccin
season
potenti
pandem
virus
deliv
either
intranas
via
convent
intramuscular
immun
mice
demonstr
excel
immunogen
protect
viral
challeng
well
singledos
protect
homolog
vaccin
virus
case
influenza
vlp
also
induc
strong
crossprotect
heterolog
virus
especi
intranas
deliveri
sever
intranas
influenza
vlp
vaccin
evalu
human
promis
result
review
refer
intranas
rout
deliveri
influenza
vaccin
offer
dual
advantag
elicit
mucos
immun
provid
broader
protect
site
viru
entri
addit
intranas
vaccin
may
facilit
mass
vaccin
case
immin
pandem
threat
studi
test
efficaci
intranas
vlp
induc
immun
homolog
heterolog
influenza
virus
use
ferret
model
close
reflect
human
infect
viru
vaccin
cell
influenza
viru
mdck
isol
use
produc
vlp
use
antigen
antibodi
hemagglutin
inhibit
hi
enzymelink
immunosorb
assay
elisa
highli
homolog
use
singl
radial
immunodiffus
srid
assay
use
elisa
antigen
season
antibodi
virus
use
elisa
antigen
grown
egg
inactiv
bpl
purifi
use
anew
york
use
homolog
challeng
viru
use
heterolog
season
influenza
challeng
virus
gener
plasmid
revers
genet
approach
virus
deriv
plasmid
transfect
cell
propag
mdck
cell
genom
result
virus
sequenc
confirm
lack
mutat
propag
mdck
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
plaqu
assay
perform
determin
viru
titer
use
monolay
mdkc
cell
standard
procedur
commerci
monoval
split
vaccin
contain
sanofipasteur
swiftwat
pa
handl
store
accord
manufactur
recommend
vaccin
use
manufactur
recommend
expir
date
vlp
product
character
cdna
encod
hemagglutinin
ha
facilit
format
vlp
human
pandem
viru
mdck
isol
subclon
baculoviru
shuttl
vector
recombin
baculovirus
express
ha
gener
previous
describ
vlp
contain
ha
viru
produc
insect
cell
purifi
character
previous
describ
briefli
vlp
releas
cultur
supernat
harvest
concentr
use
hollow
fiber
filtrat
system
subsequ
purifi
sucros
gradient
ultracentrifug
amount
ha
incorpor
vlp
initi
determin
western
blot
analysi
hemagglutin
assay
previous
describ
subsequ
singl
radial
immunodiffus
srid
assay
srid
assay
potenc
vlp
vaccin
test
singl
radial
immunodiffus
srid
describ
previous
briefli
refer
antigen
sheep
haspecif
antisera
specif
obtain
nation
institut
biolog
standard
control
nibsc
vlp
refer
antigen
treat
zwitterg
min
room
temperatur
appli
appropri
hole
prepar
agar
gel
contain
antisera
accord
nibsc
instruct
follow
h
incub
gel
stain
coomassi
brilliant
blue
visual
zone
antigenantibodi
precipit
destain
gel
dri
diamet
zone
produc
vlp
refer
antigen
measur
concentr
ha
vlp
calcul
valu
obtain
refer
antigen
ferret
immun
viral
challeng
male
fitch
ferret
mustela
putoriu
furo
month
age
tripl
f
farm
sayr
pa
use
studi
anim
serolog
neg
base
result
hi
test
current
circul
influenza
virus
two
group
ferret
receiv
g
ha
vlp
ml
per
inject
g
ha
commerci
monoval
split
inactiv
viru
vaccin
ml
per
inject
via
intramuscular
im
inject
anoth
two
group
anim
immun
g
ha
vlp
via
intranas
inocul
inocul
ferret
sedat
im
inject
ketaminexylazin
laid
back
ml
vlp
instil
dropwis
nare
half
nostril
use
syring
plastic
cathet
attach
booster
immun
given
day
postimmun
blood
collect
ferret
first
immun
day
immun
day
first
immun
day
boost
sera
treat
receptordestroy
enzym
rde
ii
seiken
denka
seiken
co
ltd
tokyo
japan
heat
inactiv
test
hemagglutin
inhibit
hi
assay
sera
also
test
total
virusbind
igg
use
enzymelink
immunosorb
assay
elisa
day
first
immun
day
boost
anim
challeng
intranas
ml
phosphatebuff
salin
pb
contain
pfu
homolog
viru
heterolog
viru
describ
previous
control
group
ferret
also
infect
morbid
assess
daili
measur
bodi
weight
temperatur
bodi
temperatur
monitor
use
electron
transpond
chip
implant
subcutan
shoulder
blade
read
electron
probe
biomed
data
system
inc
seaford
de
nasal
wash
collect
describ
previous
day
infect
addit
two
ferret
experiment
control
group
euthan
day
infect
determin
viral
titer
tissu
organ
olfactori
bulb
brain
nasal
turbin
tonsil
trachea
lung
small
larg
intestin
harvest
weigh
homogen
volum
cold
phosphatebuff
salin
pb
yield
wtvol
suspens
materi
clarifi
centrifug
g
supernat
use
viru
quantif
viru
titer
determin
plaqu
assay
mdck
cell
express
log
pfu
ml
nasal
wash
g
tissu
sampl
limit
viru
detect
pfu
per
ml
nasal
wash
pfu
per
g
organ
tissu
anim
experi
conduct
enhanc
anim
biosafeti
level
facil
center
diseas
control
prevent
protocol
approv
iacuc
hi
assay
hi
assay
perform
previous
describ
briefli
receptordestroy
enzymetr
serum
sampl
l
incub
equal
volum
inactiv
viru
hemagglutin
unit
hau
homolog
heterolog
assay
respect
room
temperatur
min
incub
equal
volum
turkey
erythrocyt
ad
incub
h
hi
titer
express
reciproc
highest
dilut
sampl
prevent
hemagglutin
elisa
influenza
virusspecif
antibodi
titer
determin
elisa
influenza
virus
grown
day
embryon
egg
allanto
fluid
harvest
bpl
inactiv
virus
pellet
highspe
ultracentrifug
purifi
sucros
gradient
centrifug
bplinactiv
influenza
virus
concentr
gml
use
coat
antigen
sodium
bicarbon
buffer
ph
microtit
plate
h
follow
h
plate
wash
pb
incub
h
bovin
serum
albumin
bsa
pb
block
remain
bind
site
twofold
serial
dilut
ferret
serum
ad
well
incub
h
remov
test
sampl
subsequ
wash
time
pb
plu
tween
pbst
dilut
mgml
monoclon
mous
antimustelid
igg
abd
serotec
oxford
unit
kingdom
goat
antiferret
iga
bethyl
laboratori
montgomeri
tx
ad
well
plate
incub
h
plate
wash
time
pbst
dilut
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
alpha
diagnost
intern
san
antonio
tx
rabbit
antigoat
igg
bethyl
laboratori
montgomeri
tx
ad
well
plate
incub
h
follow
remov
conjug
wash
addit
ophenylenediamin
opd
h
substrat
final
absorb
read
nm
influenza
vaccin
standard
base
amount
ha
contain
vaccin
compar
studi
import
quantifi
normal
ha
content
differ
vaccin
previous
describ
ha
predominantli
precursor
form
major
compon
vlp
vaccin
vlp
roughli
spheric
approxim
nm
diamet
previous
describ
concentr
ha
vlp
measur
srid
test
use
refer
antigen
sridcalibr
antisera
nibsc
homolog
found
mgml
vlp
commerci
monoval
split
vaccin
dose
amount
ha
use
immun
group
ferret
im
rout
antibodi
respons
vlp
vaccin
ferret
neg
influenza
virusspecif
respons
prior
immun
immun
ferret
respond
singl
dose
vlp
deliv
either
im
g
g
inocul
moder
serum
antibodi
titer
hi
homolog
viru
fig
high
hi
titer
develop
serum
second
dose
vlp
comparison
split
commerci
vaccin
moder
immunogen
two
dose
g
ha
given
im
reach
lower
hi
titer
either
rout
vlp
p
mannwhitney
u
test
fig
serum
antibodi
respons
homolog
viru
measur
elisa
plate
coat
whole
viru
antigen
parallel
hi
titer
vlp
either
im
induc
moder
titer
antivir
antibodi
homolog
viru
singl
immun
high
titer
booster
vaccin
split
vaccin
induc
moder
level
antibodi
homolog
antigen
booster
dose
fig
titer
significantli
lower
either
rout
vlp
immun
p
mannwhitney
u
test
specif
iga
antibodi
detect
immun
three
vaccin
although
titer
lower
variabl
im
deliveri
fig
result
suggest
vlp
vaccin
immunogen
split
vaccin
crossreact
sera
ferret
heterolog
season
influenza
antigen
observ
hi
assay
fig
hi
titer
limit
detect
regardless
rout
form
immun
contrast
hi
titer
ferret
immun
vlp
split
vaccin
develop
moder
level
antibodi
crossreact
elisa
wholeviru
antigen
fig
assay
split
vaccin
induc
titer
equival
vlp
higher
im
vlp
presum
split
vaccin
includ
neuraminidas
na
antigen
well
ha
therefor
abl
target
antigen
march
guest
http
cviasmorg
download
wholeviru
elisa
howev
crossreact
iga
respons
detect
fig
protect
morbid
homolog
viral
challeng
assess
induct
protect
immun
vaccin
control
ferret
challeng
pfu
homolog
heterolog
viru
intranas
day
booster
vaccin
day
initi
vaccin
challeng
ferret
show
trend
toward
moder
increas
temperatur
day
fig
nonimmun
ferret
lost
approxim
bodi
weight
first
week
challeng
wherea
ferret
vaccin
vlp
either
im
show
transient
moder
weight
loss
approxim
bodi
weight
recov
lost
weight
rapidli
fig
unexpectedli
split
vaccin
confer
littl
protect
diseas
symptom
ferret
receiv
immun
lost
weight
similar
extent
control
fig
result
homolog
viru
challeng
suggest
vlp
vaccin
might
provid
better
protect
split
vaccin
evidenc
less
bodi
weight
loss
protect
homolog
viral
replic
shed
vlp
vaccin
also
provid
signific
protect
viral
shed
even
first
day
challeng
anim
shed
high
titer
viru
nasal
wash
ferret
vaccin
vlp
either
rout
im
show
significantli
reduc
viru
shed
p
mannwhitney
u
test
fifth
day
postchalleng
viru
undetect
ferret
immun
vlp
easili
detect
level
viru
still
shed
ferret
well
immun
split
vaccin
fig
assess
impact
vaccin
viru
replic
day
infect
two
ferret
sacrif
viral
titer
measur
olfactori
bulb
brain
nasal
turbin
tonsil
trachea
lung
small
larg
intestin
ferret
easili
detect
level
viru
organ
test
except
brain
fig
three
vaccin
regimen
vlp
split
vaccin
reduc
undetect
level
viral
titer
larg
small
intestin
olfactori
bulb
ferret
receiv
either
im
vlp
also
undetect
level
viru
tonsil
trachea
immun
split
vaccin
detect
viru
tonsil
lower
level
ferret
ferret
receiv
vlp
receiv
split
vaccin
reduc
viral
titer
lung
nasal
turbin
compar
control
fig
one
ferret
receiv
vlp
detect
viru
lung
ferret
receiv
im
vlp
detect
viru
lung
fig
result
indic
immun
either
vlp
split
vaccin
fig
lost
weight
least
similar
extent
fig
vaccin
ferret
show
margin
greater
weight
loss
control
p
mannwhitney
u
replic
viru
also
affect
vaccin
ferret
ferret
vaccin
vlp
subsequ
challeng
viru
shed
similar
amount
viru
nasal
wash
similar
period
fig
three
day
challeng
two
ferret
sacrif
c
day
challeng
ferret
sedat
nasal
wash
collect
viru
titer
shown
log
pfuml
determin
averag
viru
titer
group
standard
deviat
sd
shown
limit
detect
pfuml
indic
dash
line
signific
differ
mannwhitney
u
test
p
p
indic
respect
upper
row
split
vaccin
im
versu
vlp
im
lower
row
control
versu
vlp
im
three
day
infect
two
ferret
per
group
euthan
organ
sampl
indic
collect
viru
titer
determin
limit
detect
pfug
tissu
indic
dash
line
tissu
brain
blood
liver
kidney
spleen
also
test
neg
data
shown
ctrl
control
viru
titer
intern
organ
measur
viru
recov
nasal
turbin
tonsil
trachea
reach
similar
titer
vaccin
anim
fig
vlp
promis
method
vaccin
combin
high
immunogen
safeti
rapid
effici
product
vlp
investig
mani
virus
includ
hepat
c
viru
sever
retrovirus
sever
acut
respiratori
syndrom
sar
coronaviru
influenza
viru
review
refer
previou
experi
demonstr
vlp
contain
influenza
viru
ha
na
effect
prevent
homolog
case
heterolog
viral
infect
potenti
eas
use
safeti
immunogen
vlp
make
attract
option
clinic
use
could
offer
major
advantag
mass
vaccin
case
pandem
intranas
vaccin
demonstr
induc
broader
rang
protect
lethal
challeng
addit
vaccin
attract
option
clinic
avoid
inject
test
immunogen
protect
b
ferret
bodi
weight
monitor
daili
averag
bodi
weight
group
sd
percentag
bodi
weight
day
signific
differ
mannwhitney
u
test
p
indic
c
day
challeng
ferret
sedat
nasal
wash
collect
viru
titer
shown
log
pfuml
determin
averag
viru
titer
group
sd
shown
limit
detect
pfuml
indic
dash
line
three
day
infect
two
ferret
per
group
euthan
organ
sampl
indic
collect
viru
titer
determin
limit
detect
pfug
tissu
indic
dash
line
tissu
brain
blood
liver
kidney
spleen
also
test
neg
data
shown
ctrl
control
vaccin
ferret
vlp
contain
ha
protein
induc
high
antibodi
titer
confer
signific
protect
homolog
viru
challeng
vlpvaccin
anim
lost
less
weight
shed
less
viru
nasal
wash
markedli
lower
viru
titer
organ
test
control
singl
dose
vlp
either
im
induc
higher
level
antibodi
two
dose
commerci
split
vaccin
although
antibodi
respons
split
vaccin
detect
hi
elisa
especi
remark
elisa
titer
detect
antibodi
respons
wide
rang
viral
antigen
well
hi
titer
higher
vlp
even
though
split
vaccin
includ
na
well
ha
provid
addit
antigen
target
antibodi
respons
fact
broader
respons
induc
split
vaccin
observ
elisa
heterolog
viru
split
vaccin
induc
equal
titer
antibodi
vlp
higher
im
vlp
assay
antibodi
might
direct
conserv
region
ha
neutral
viru
prevent
hemagglutin
detect
explain
signific
elisa
titer
heterolog
viru
correspond
detect
hi
titer
ferret
vaccin
split
vaccin
incomplet
protect
challeng
although
anim
lower
viru
titer
olfactori
bulb
tonsil
intestin
lost
weight
shed
viru
nasal
wash
similar
extent
control
immunogen
protect
efficaci
split
vaccin
previous
demonstr
mice
human
ferret
howev
split
vaccin
previous
shown
weakli
immunogen
partial
protect
consist
observ
human
vaccin
split
vaccin
probabl
prime
previou
exposur
season
virus
therefor
react
vigor
ferret
challeng
dose
present
experi
pfu
may
high
control
modest
level
antibodi
induc
split
vaccin
case
vlp
vaccin
either
im
rout
capabl
dramat
reduc
viral
replic
diseas
even
challeng
dose
reinforc
superior
immunogen
vlp
previou
experi
vlp
vaccin
shown
induc
rel
broad
crossprotect
heterolog
virus
subtyp
mice
especi
deliv
test
abil
vlp
confer
protect
challeng
heterolog
season
influenza
viru
despit
high
titer
antibodi
homolog
virus
hi
elisa
moder
elisa
titer
heterolog
viru
antibodi
detect
hi
assay
indic
antibodi
respons
heterolog
viru
direct
conserv
region
ha
capabl
block
bind
ha
receptor
consist
vlp
confer
littl
crossprotect
challeng
viru
reveal
lack
reduct
nasal
wash
viru
titer
similar
viru
titer
organ
lack
protect
diseas
indic
similar
level
weight
loss
previou
studi
vlp
mice
develop
partial
crossprotect
differ
heterolog
viru
one
possibl
mice
readili
protect
influenza
viru
infect
even
minim
level
crossreact
immun
respons
exampl
partial
crossprotect
observ
mice
antibodi
titer
reactiv
heterolog
viru
lower
compar
reactiv
homolog
viru
like
protect
immun
difficult
achiev
ferret
like
human
intrins
suscept
influenza
viru
mice
well
ha
heterolog
challeng
viru
use
studi
close
relat
viru
challeng
viru
use
previous
make
crossprotect
difficult
achiev
inde
lack
crossprotect
immun
even
infect
wildtyp
virus
virus
virus
may
explain
rapid
global
spread
viru
even
though
vlp
deliv
immunogen
split
vaccin
induc
crossreact
antibodi
appar
antibodi
lack
critic
protect
function
studi
necessari
fulli
understand
extent
crossprotect
immun
vlp
vaccin
identifi
vaccin
method
consist
induc
broadli
protect
immun
respons
summari
experi
demonstr
strong
immunogen
protect
efficaci
vlp
compar
split
vaccin
show
deliveri
vlp
potenti
highli
efficaci
vaccin
influenza
work
support
part
nihniaid
grant
rwc
rwc
research
support
part
appoint
research
particip
program
center
diseas
control
prevent
administ
oak
ridg
institut
scienc
educ
interag
agreement
us
depart
energi
cdc
thank
staff
anim
resourc
branch
cdc
outstand
anim
care
thank
center
biolog
evalu
research
fda
provid
srid
reagent
find
conclus
report
author
necessarili
repres
view
center
diseas
control
prevent
agenc
toxic
substanc
diseas
registri
potenti
conflict
interest
smk
rwc
emori
univers
equiti
interest
zetra
biolog
develop
viruslik
particl
technolog
licens
emori
univers
alter
adher
nih
polici
share
data
materi
